French AFU Cancer Committee Guidelines – Update 2026–2028: Prostate cancer – Diagnosis and management of localized disease - 20/11/26
, Michaël Baboudjian c, r, Eric Barret d, r, Laurent Brureau e, r, Gaëlle Fiard f, r, Gaëlle Fromont g, r, Jonathan Olivier h, r, Charles Dariane i, r, Romain Mathieu j, r, François Rozet d, r, Arthur Peyrottes k, r, Guilhem Roubaud l, r, Raphaële Renard-Penna m, r, Paul Sargos n, r, Stéphane Supiot o, r, Léa Turpin p, r, Morgan Rouprêt q, rAbstract |
Objective |
The aim of the Cancer Committee of the French Association of Urology is to propose an update of the recommendations for the diagnosis and management of localized prostate cancer (PCa).
Methods |
A systematic review of the literature from 2024 to 2026 concerning the diagnosis and therapeutic management of localized PCa was conducted by the CCAFU, and the references and their level of evidence were evaluated.
Results |
The recommendations specify the genetics, epidemiology, and diagnostic methods of prostate cancer, as well as screening and early detection approaches. Disease staging is performed on the basis of clinical and biological data, MRI, and molecular imaging. Therapeutic options are detailed and recommended according to clinical situations, along with posttreatment monitoring.
Conclusion |
This update of the French recommendations should contribute to improving the management of localized prostate cancer.
Le texte complet de cet article est disponible en PDF.Keywords : Prostate cancer, Diagnosis, Treatment, Guidelines, Screening
Plan
Vol 36 - N° 11
Article 103191- janvier 2026 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
